Anti-Hypertensive Drugs

Global Anti-Hypertensive Drugs Market to Reach US$29.7 Billion by 2030

The global market for Anti-Hypertensive Drugs estimated at US$25.3 Billion in the year 2024, is expected to reach US$29.7 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Calcium Channel Blockers, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$7.2 Billion by the end of the analysis period. Growth in the ACE Inhibitors segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.8 Billion While China is Forecast to Grow at 4.7% CAGR

The Anti-Hypertensive Drugs market in the U.S. is estimated at US$6.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 4.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Anti-Hypertensive Drugs Market - Key Trends and Drivers Summarized

The global market for anti-hypertensive drugs is a major segment within the pharmaceutical industry, driven largely by the widespread prevalence of hypertension, which affects approximately 1.5 billion people worldwide. Despite hypertension being one of the most common chronic diseases globally, there has been a noticeable decline in innovative research on blood pressure mechanisms and new treatments in recent years. This decline is particularly concerning given the rising burden of the disease, especially in low-income countries, coupled with ongoing issues of underdiagnosis and undertreatment in wealthier nations.

The demand for anti-hypertensive medications continues to grow, fueled by an aging population, increasing rates of obesity, sedentary lifestyles, and poor dietary choices such as high salt intake. In response, the market is seeing a shift towards the development of new drug therapies that offer better efficacy, reduced side effects, and improved patient compliance, such as combination therapies that incorporate multiple drugs in a single dosage form to simplify treatment regimens. Furthermore, advancements in genomics and biotechnology are paving the way for more personalized approaches to treatment, allowing for medications to be tailored to the genetic profiles of individual patients, enhancing the effectiveness of hypertension management.

Emerging economies are witnessing significant growth in access to anti-hypertensive treatments, driven by expanding middle classes and better health insurance coverage. This expansion is supported by government and healthcare initiatives aimed at increasing public awareness about the risks of high blood pressure and promoting effective management practices. Additionally, the rise of home health monitoring technologies, such as digital blood pressure monitors linked to smartphone apps, is promoting better patient engagement and adherence to treatment by enabling patients to monitor their condition in real-time. However, the industry also faces challenges such as stringent regulatory environments and pressure to reduce drug prices, which are pushing pharmaceutical companies to innovate in cost-effective drug production and distribution methods.

 

SCOPE OF STUDY:

The report analyzes the Anti-Hypertensive Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators, Other Types)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 143 Featured) -

• Actelion Pharmaceuticals Ltd.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Co., Ltd.
• Johnson & Johnson
• Lupin Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi
• Takeda Pharmaceutical Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.